United Arab Emirates
Diabetes country report 2011 — 2050
Number of adults (20–79 years) with diabetes in United Arab Emirates (AE)
2011 | 768.0 thousand |
2024 | 1.3 million |
2050 | 1.9 million |
United Arab Emirates is one of the 21 countries and territories in the IDF Middle-East and North Africa Region.
Data source(s) used for the diabetes estimates in adults:
- Sulaiman N, Albadawi S, Abusnana S, et al. Sci Rep 2018;8:6862. https://doi.org/10.1038/s41598-018-24312-3. PMID:29717208
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | - | 768.0 | 1,274.2 | 1,876.5 |
Age-standardised prevalence of diabetes, % | - | 18.8 | 20.7 | 22.7 |
Proportion of people with undiagnosed diabetes, % | - | - | 64.0 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 815.5 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 1,301.1 | 1,574.3 |
Age-standardised prevalence of IFG, % | - | - | 17.0 | 17.3 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 817.8 | 1,220.6 | 1,702.9 |
Age-standardised prevalence of IGT, % | - | 16.3 | 18.2 | 19.7 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 1,427.0 | 829.9 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 10.9 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | 31,436.4 | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | 30.3 | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | 5,306.7 | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | 2,985.0 | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 2,017.8 | 2,484.3 |
Total diabetes-related health expenditure, ID million | - | - | 3,522.5 | 4,336.9 |
Diabetes-related health expenditure per person, USD | - | 1,775.0 | 1,583.5 | 1,323.9 |
Diabetes-related health expenditure per person, ID | - | - | 2,764.4 | 2,311.2 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 79,074.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 9,939.3 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | - | 6,107.4 | 7,710.7 | 9,281.4 |
Population of children and adolescents (0-19 y) | - | - | 2,279,353.5 | - |
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | - |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | - |
Population of children and adolescents (0-19 y) | - |